Trial Profile

An Open-Label, First-in-human, Safety and Pharmacokinetic Study of 1-Month Sustained-Release Injectable Tacrolimus in Healthy Subjects

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 12 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary)
Indications Psoriasis; Transplant rejection
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Auritec Pharmaceuticals

Most Recent Events

10 Jan 2019 Status changed from active, no longer recruiting to completed.
07 Nov 2018 Status changed from recruiting to active, no longer recruiting.
23 Oct 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 16 Aug 2018 to 15 Nov 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com